Cancers, Free Full-Text

Neuroblastoma is the most common extracranial solid pediatric tumor, with around 15% childhood cancer-related mortality. High-risk neuroblastomas exhibit a range of genetic, morphological, and clinical heterogeneities, which add complexity to diagnosis and treatment with existing modalities. Identification of novel therapies is a high priority in high-risk neuroblastoma, and the combination of genetic analysis with increased mechanistic understanding—including identification of key signaling and developmental events—provides optimism for the future. This focused review highlights several recent findings concerning chromosomes 1p, 2p, and 11q, which link genetic aberrations with aberrant molecular signaling output. These novel molecular insights contribute important knowledge towards more effective treatment strategies for neuroblastoma.

The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines - ScienceDirect

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

National Comprehensive Cancer Network - Home

What is cancer of unknown primary (CUP)?

Cancer - Wiley Online Library

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Kidney Cancer: Symptoms, Signs, Causes & Treatment

Working with Filters - My NCBI Help - NCBI Bookshelf

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers - European Urology Focus

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization